Hepatitis C virus treatment response to sofosbuvir/ledipasvir among adolescents coinfected with HIV and HCV: Real world data from Ukraine

European Meeting on HIV & Hepatitis 2021

Pharmacist-led telephone clinic is an effective strategy for treating patients with hepatitis C and removing barriers to attending appointments

European Meeting on HIV & Hepatitis 2021

A Public Health Approach to Sustainability of Community Based HCV Treatment among HIV/HCV Co-infected KPs through programmatic cost efficiency in Ukraine

European Meeting on HIV & Hepatitis 2021

How Carbon Nanotubes can orchestrate the immunological response? Perspectives in vaccine application

European Meeting on HIV & Hepatitis 2021

Frequency of IN gene region polymorphisms associated with ALLINIs effectiveness in HIV-1 subtype A6 dominating in Russia

European Meeting on HIV & Hepatitis 2021

Pretreated drug-resistance in newly diagnosed HIV-1 patients in Portugal between 2014 and 2019

European Meeting on HIV & Hepatitis 2021

Application of the genetic diversity analysis for determination of HIV infection duration

European Meeting on HIV & Hepatitis 2021

Integrase genotyping is highly effective on diverse HIV-1 non-B clades circulating in Cameroon: toward a successful transition to Dolutegravir-based regimens in Africa

European Meeting on HIV & Hepatitis 2021

Comparison of the new Cepheid HIV VL XC Assay with the established Abbott Alinity m in HIV-1 viral load measurement

European Meeting on HIV & Hepatitis 2021

Sensitivity of ultra-deep sequencing for dual HIV infection detection

European Meeting on HIV & Hepatitis 2021

Molecular epidemiology of SARS-CoV-2 in Greece reveals low rates of onward virus transmission after lifting of travel restrictions based on risk assessment during summer 2020

European Meeting on HIV & Hepatitis 2021

Characterization and Resistance Profile of “Unusual” Hepatitis C Virus (HCV) Subtypes in Italy

European Meeting on HIV & Hepatitis 2020

Infection with subtype D adversely affects the live expectancy among people living with HIV – data from Northwestern Poland

European Meeting on HIV & Hepatitis 2020

HIV TRACE vs phylogenetic analysis: unraveling transmission clusters in Spain

European Meeting on HIV & Hepatitis 2020

Prevalence and evolution of transmitted HIV drug resistance in Belgium between 2013 and 2019

European Meeting on HIV & Hepatitis 2020

Factors associated with the emergence of resistance mutations in patients failing dual or triple-integrase inhibitors-based regimen in a French national survey

European Meeting on HIV & Hepatitis 2020

HIV DNA drug resistance genotyping, based on illumina sequencing, as decisional marker for cart opimisation in clinical practice: added value, gaps and future directions

European Meeting on HIV & Hepatitis 2020

High efficacy after switching to integrase strand transfer inhibitors (INSTI) in PLWH with undetectable viremia and past virological failure and/or resistance

European Meeting on HIV & Hepatitis 2020

Emergence and Persistence of Integrase Mutation T97A Selected by Dolutegravir

European Meeting on HIV & Hepatitis 2020

Evaluation of HIV-1 RNA and DNA mutational load in HIV-1 infected heavily treatment-experienced patients harbouring multi-drug resistant strains

European Meeting on HIV & Hepatitis 2020

Long-term Bictegravir and Dolutegravir Resistance Selections Initiated with HIV-1 Containing M184V in Reverse Transcriptase

European Meeting on HIV & Hepatitis 2020

Molecular analysis of HCV subtype 3a dispersal patterns among inmates in Greece: HCV transmissions are not related to incarceration

European Meeting on HIV & Hepatitis 2020

Highly sensitive digital droplet PCR assay allows to reveal cryptic HBV replication in anti-HBc positive/HBsAg negative patients with HIV infection.

European Meeting on HIV & Hepatitis 2020

Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates

European Meeting on HIV & Hepatitis 2020